Skip to main content

30-09-2017 | EGFR inhibitors | Article

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Shi YH et al. Ann Oncol 2017; 28(10): 2443-2450. doi:10.1093/annonc/mdx359

Please log in to get access to this content

Related topics

Have your say on Medicine Matters

Visit the conference hub

Image Credits